PMD was founded to void the fundamental clinical need to measure patients breathing rates, which if amiss, is a significant indicator of an adverse event.
During 2010, working with Cork University Hospital’s Emergency Department and resident Professor of Emergency Medicine, Mr Stephen Cusack, we developed a new to world technology that revolutionises the way this lost vital sign is measured.
Since its inception PMD has developed ground breaking medical devices for the monitoring and diagnosis of respiratory conditions with the fundamental belief of making every breath count.
PMD Solutions, founded in 2011, develop innovative and patient friendly technologies to support health provider’s early prevention model of patient care. PMD continues its operations in Bishopstown House, Model Farm Road, Cork, Ireland.
PMD was founded on a fundamental clinical need to measure a patients breathing rate, which if amiss, is a significant indicator that something is wrong with the patient. During 2010, working with Cork University Hospital’s Emergency Department and resident Professor of Emergency Medicine Stephen Cusack, PMD developed a viable technology to revolutionise the way this lost vital sign was measured. Since then, PMD has developed ground breaking medical devices for the monitoring and diagnosis of respiratory conditions with the fundamental belief of making every breath count, PMD can improve patient outcomes.
While the core technology has several clinical applications today, the primary focus of the technology was to address the technological deficit of accurate and continuous respiratory rate monitoring. Since early 2000, healthcare systems around the world were trying to adapt to manage an ageing population and reducing healthcare budgets. From this economic pressure came the focus on preventative monitoring – the ability to risk stratify patients according to probable level of future severity. This is known as Early Warning Scoring. The measuring of several vital signs including Respiratory Rate, Heart Rate, Blood Pressure, Temperature, and Blood Oxygen Levels.
Although the significance of respiratory rate monitoring as the earliest and most sensitive indicator of patient deterioration had been well published as far back as the 1920’s, the infrastructure for acting upon with was enabled through the deployment of Early Warning Scoring. Further research development from 2010 onwards began to quantify respiratory rates early and specific predictors of patient outcomes including a study by Dr. Goldhill, anaesthetist of The Royal National Orthapaedic Hospital, Stanmore, UK, reports that 21% of patients having an RR of between 25-29 breath per minute had an event, with said indictor showing 24 hours before the adverse event, ahead of any other change in the other vital signs, with 95% specificity.
Since the launch of RespiraSense in 2014, PMD has continued its research activities to launch a new product in 2016 that seeks to address the undiagnosed 94% of the population suffering with Sleep disorders. Sleep apnoea, a condition resulting in breaks in breathing effort during sleep, has significant health and lifestyle implications if left untreated. Today, 3-4% of the global population suffers from sleep apnoea with 94% still waiting to be tested, diagnosed, and prescribed a treatment such a Continuous Positive Airway Pressure (CPAP). PMD has leveraged the same technology used for continuous respiratory rate monitoring in the form of a Home Sleep Test – no more belts and no more nasal cannulas. Just apply, and within 24 hours of the test being completed, treatment can be prescribed. More importantly, it will enable sleep consultants to increase their patient coverage by over 200% with minimum increase in resources.
The value of respiratory rate monitoring for the early identification of patient deterioration is evident and the clinical need for accelerated diagnosis for sleep apnoea is urgent. PMD seeks to improve patient’s outcomes by making every breath count through continuous Respiratory rate monitoring for general care floor and simple home sleep Tests for patients around the world. Positioning PMD’s technology as the industry standard in respiratory effort monitoring by 2020.
Product trial in Cork University Hospital
PMD Solutions develops its first working prototype
PMD appoints Stephen Cusack as the company’s Clinical Director
PMD is selected for the Genesis Enterprise Program
PMD graduates from the GE programme as a finalist of the Genesis Enterprise Emerging Business of the Year award
PMD awarded Best of Class at Cork Entrepreneurial Experience
Awarded a founding place on the NDRC’s VentureLab program
PMD and Gentian Services join resources to bring RespiraSense to commercialisation
Wins Highly Commended Award from Intertrade Ireland All-Island Seedcorn Competition
PMD raises €450,000 through Enterprise Ireland, Industrial, and Angel investment
RepiraSense performs expertly during clinical trial in UHC
PMD is awarded Enterprise Ireland High Potential Start-Up status
PMD attends Medtec for the first time
Start-Up Academy of Excellence Winner
IMDA Medical Technology Industry Excellence Emerging Company of the Year
RespiraSense gets CE Mark approval
PMD secures €4.2 million in funding from Horizon 2020 SME Instrument
PMD wins dotMED 2016 Health Technology award
PMD attends 12th International Conference on Rapid Response Systems and Medical Emergency Teams in Melbourne
PMD Solutions Announces Successful FDA Pre Submission Meeting and Progresses with Plans for FDA 510K Submission in 2017 ‘RespiraSense’ PMD Solutions, an Irish Medical Technology firm, announces a successful Pre Submission meeting with the FDA for ‘RespiraSense’, the world’s first respiratory rate wearable specifically designed for trend monitoring of acute…